Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Because of the high risk for development of muscle invasive disease, cystectomy is
recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence
following intravesical therapy. VB4-845 injection is an experimental agent that may provide
an alternative to cystectomy